SCTX logo

Scribe Therapeutics Inc.

SCTX
Healthcare|Biotechnology|US
$15.70
+0.22 (+1.42%)
Next Earnings Report
Dec 2, 2026
EPS est. -$0.42 · Revenue est. $3.7M
Financing Filings (last 12 months)
5
Shelf registrations / offering prospectuses — latest Jul 27, 2026 (424B4). Possible dilution.

Upcoming Data Readouts (1)

Dec 2028
Est. completion
P1Elevated LDL-C and High Cholesterol
A Study of STX-1150 in Participants With Elevated Low-Density Lipoprotein Cholesterol (LDL-C)
NCT07428473n=64

Recent Press Releases

Scribe Therapeutics to Participate in Upcoming Healthcare Investor Conferences
Nov 5, 2026 · GlobeNewsWire
Scribe Therapeutics to Present Updated Data on PCSK9-Targeting Epigenetic Silencing and LPA-Targeting Gene Editing Programs at American Heart Association (AHA) Scientific Sessions 2026
Nov 4, 2026 · GlobeNewsWire
Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Sep 2, 2026 · GlobeNewsWire
Scribe Therapeutics to Participate in Upcoming Investor Conferences
Sep 1, 2026 · GlobeNewsWire

SEC Filings (20)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Sep 2, 202610-QQuarterly reportDocumentIndex
Sep 2, 20268-KMaterial eventDocumentIndex
Aug 3, 2026SC 13GPassive 5%+ stakeDocumentIndex
Jul 30, 2026SC 13DActivist / 5%+ stakeDocumentIndex
Jul 30, 2026SC 13DActivist / 5%+ stakeDocumentIndex
Jul 29, 2026SC 13DActivist / 5%+ stakeDocumentIndex
Jul 27, 20268-KMaterial eventDocumentIndex
Jul 27, 2026S-8Employee stock planDocumentIndex
Jul 27, 2026424B4Offering prospectusDocumentIndex
Jul 24, 2026FWPDocumentIndex
Jul 23, 2026EFFECTDocumentIndex
Jul 23, 2026S-1MEFIPO / offering registrationDocumentIndex
Jul 22, 2026CERTDocumentIndex
Jul 21, 20268-A12BDocumentIndex
Jul 20, 2026S-1/AIPO / offering registrationDocumentIndex
Jul 10, 2026S-1/AIPO / offering registrationDocumentIndex
Jul 2, 2026S-1IPO / offering registrationDocumentIndex
Jun 12, 2026DRS/ADocumentIndex
Mar 6, 2026DRS/ADocumentIndex
Jan 9, 2026DRSDocumentIndex